Research Shows Metastatic Brain Tumor Patients Under 50 Have Improved Survival Rates with Stereotactic Radiosurgery
Data from a study recently published in the International Journal of Radiation Oncology indicates that patients under 50 with limited metastatic brain tumors should receive stereotactic radiosurgery (SRS) without whole-brain radiation therapy (WBRT) for chances of improved survival.
Researchers analyzed patient data from three of the largest clinical trials of SRS and WBRT conducted to date. The patients were all under the age of 50 and had limited brain metastases of one to four tumors.
Results of the study show that survival was improved by 13 percentage points in patients under 50 years of age who received SRS alone, compared to those patients who received both SRS and WBRT.
“We expected to see a survival advantage favoring combined therapy of SRS and WBRT. However, these data clearly demonstrate the benefit for SRS alone to improve survival for our younger patients with limited brain metastases,” said lead author of the study Arjun Sahgal, MD.
The results of this study join findings from other recent studies confirming the efficacy of SRS for brain tumors and other neurological diseases. To read more about the study and findings, click here.
To learn more about how Louisville CyberKnife treats brain tumors with SRS using advanced CyberKnife® technology, read our blog series here.
This is not intended as medical advice to replace the expertise and judgment of your health care team. It is intended to help you and your family make informed decisions, together with your doctor.